- Home
- TLSA vs PSNL Comparison
TLSA vs PSNL Comparison
Compare TLSA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- PSNL
- Stock Information
- Founded
- TLSA 2013
- PSNL 2011
- Country
- TLSA United Kingdom
- PSNL United States
- Employees
- TLSA N/A
- PSNL N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- TLSA Health Care
- PSNL Health Care
- Exchange
- TLSA Nasdaq
- PSNL Nasdaq
- Market Cap
- TLSA 87.8M
- PSNL 321.1M
- IPO Year
- TLSA 2000
- PSNL 2019
- Fundamental
- Price
- TLSA $1.20
- PSNL $5.19
- Analyst Decision
- TLSA
- PSNL Strong Buy
- Analyst Count
- TLSA 0
- PSNL 4
- Target Price
- TLSA N/A
- PSNL $6.81
- AVG Volume (30 Days)
- TLSA 145.8K
- PSNL 439.4K
- Earning Date
- TLSA 05-10-2024
- PSNL 11-06-2024
- Dividend Yield
- TLSA N/A
- PSNL N/A
- EPS Growth
- TLSA N/A
- PSNL N/A
- EPS
- TLSA N/A
- PSNL N/A
- Revenue
- TLSA N/A
- PSNL $80,027,000.00
- Revenue This Year
- TLSA N/A
- PSNL $10.85
- Revenue Next Year
- TLSA N/A
- PSNL $8.77
- P/E Ratio
- TLSA N/A
- PSNL N/A
- Revenue Growth
- TLSA N/A
- PSNL 19.20
- 52 Week Low
- TLSA $0.41
- PSNL $0.89
- 52 Week High
- TLSA $1.74
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- PSNL 56.29
- Support Level
- TLSA $0.83
- PSNL $4.54
- Resistance Level
- TLSA $0.92
- PSNL $5.35
- Average True Range (ATR)
- TLSA 0.09
- PSNL 0.30
- MACD
- TLSA 0.03
- PSNL 0.05
- Stochastic Oscillator
- TLSA 84.52
- PSNL 84.71
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.